Variants in mitochondrial DNA (mtDNA) and nuclear genes encoding mitochondrial proteins in bipolar disorder, depression, or other psychiatric disorders have been studied for decades, since mitochondrial dysfunction was first suggested in the brains of patients with these diseases. Candidate gene association studies initially resulted in findings compatible with the mitochondrial dysfunction hypothesis. Many of those studies, however, were conducted with a modest sample size (such as n < 1000), which could cause false positive findings.
Introduction
The mitochondrial DNA (mtDNA) is the genetic material of mitochondria, the intracellular organelles that are present in almost all cells of the body. There are vast differences in patterns of genetic inheritance and variations between mtDNA and the nuclear genome.
MtDNA was a target of genetic analysis prior to the nuclear genome, as mtDNA is overwhelmingly smaller (1.7 × 10 4 bp vs. 3.2 × 10 9 bp; Figure 1 ) and there are hundreds or thousands of copies of mtDNA in each cell (1, 2) . The complete sequence of human mtDNA was determined more than 20 years earlier than the completion of the human genome project (3).
The more, however, we understand mtDNA and mitochondria the more difficult target mtDNA turns out to be in genetics. Since mtDNA is maternally transmitted and does not appear to undergo recombination, conventional family-based association studies cannot be applicable, and mtDNA polymorphisms cannot be treated as independent polymorphisms.
Thus, entire mtDNA sequence should be analyzed as if it is one genotype, which is called as a haplogroup. Because haplogroups vary greatly across human populations (4) , genetic association studies of mtDNA are subject to a larger degree of population stratification than those on the nuclear genome. A simulation test predicted ~6,000 cases and a similar number of controls are required to achieve 90% power to detect 10% change in the frequency even when the most common haplogroup is associated (5) . A case-control association study of mtDNA polymorphisms in ~50,000 individuals from 11 common diseases and controls identified several polymorphisms that associated with several diseases, including schizophrenia, after multiple testing correction (6) . However, analysis of functional effect of each mtDNA polymorphism would be hampered by other polymorphisms within the same haplogroup. For example, we showed that mitochondrial calcium levels M A N U S C R I P T
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4 were lower in cybrids (transmitochondrial hybrid cells) with m.10398A>G (7) that is protective for multiple diseases (6) . However, m.10398A>G was closely linked to another polymorphism, m.8701A>G, and it was difficult to assess the functional effects of the two polymorphisms separately (7) . Rare variants, which are present sporadically across haplotypes, also interfere with association studies and functional analyses. Another complicating factor is heteroplasmy (8) , which refers to the presence of two (or more) different sequences of mtDNA in a single individual cell. In patients with a mitochondrial disease caused by a maternally inherited heteroplasmic mtDNA mutation, such as m.3243A>G in MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes; OMIM 540000), the ratio of mutant mtDNA as compared to the wild-type, varies among cells and tissues, and the clinical manifestations vary among individuals (8) (9) (10) . Modifier genes in the nuclear genome are also suggested to account for the individual difference (11) . Further complicating matters is the fact that the somatic mutation rate of mtDNA is much higher than that of the nuclear genome (12) (13) (14) . An inability to detect mutations in blood cells cannot exclude the possibility that the brain (or other organs) of a patient carries somatic mutations. In order to clarify the relationship between mtDNA mutations and mood disorders and to test the mitochondrial dysfunction hypothesis of the diseases (15) (16) (17) , it is of great significance to study mental symptoms in mitochondrial disease patients and in animal models with mtDNA mutations (16) .
Here, we overview the latest knowledge on the unique characteristics of mtDNA and the relationship between mtDNA mutations and Parkinson's disease (PD) as a model case of mtDNA mutation-associated nervous system disease. We then briefly summarize knowledge from researches on polymorphisms and deletions of mtDNA in patients with mood disorders and review the researches on psychiatric symptoms of mitochondrial M A N U S C R I P T
5 disease patients and those of animal models. The challenges and future directions after mtDNA analysis will also be discussed.
The Current Understanding of mtDNA
Over a period of a billion years since commencement of symbiosis, the origin of mitochondria, most of the symbiotic genome has been transferred to the host genome.
SAR11, the Rickettsiales (Alphaproteobacteria) that is closest to the inferred symbiotic bacteria (18, 19) have a genome of about 1,000 kb, whereas the human mtDNA is no longer than16.6 kb ( Figure 1 ). It carries 13 protein-coding genes, two mitochondrial rRNAs, and 22 mitochondrial tRNAs. All of the 13 proteins are involved in the mitochondrial oxidative phosphorylation (OXPHOS) (Figure 1 ). The other genes essential for mitochondrial biology are encoded by the nuclear genome; of the approximately 20,000 genes in the human nuclear genome, at least 1,100 genes are estimated to encode proteins that are transported to and function in the mitochondria (20) (see Figure 2 ). According to the endosymbiotic theory, transferring of mtDNA genes to the nuclear genome has been beneficial for mtDNA (the endosymbiont genome) because the mutation rate of mtDNA is much higher than that of the nuclear DNA (21, 22) . Mitochondria generate a lot of reactive oxygen species (ROS)
as by-products of the mitochondrial respiration process, and the repair system of mtDNA is less efficient than that of the nuclear DNA (23) . In addition, humans and other eukaryotes have a diploid genome and the sex system, which robustly protect endosymbiont-derived genes in the nuclear genome. The main mutagenic product of base damage in mtDNA is 8-oxoguanine, causing G→T transversion upon replication (24) . This is the first step of a vicious cycle of ROS generation and mtDNA mutations. ROS produced by respiration cause mtDNA mutations, which lead to dysfunction in the electron transport chain and to a further
increase in ROS generation due to this dysfunction (25, 26) .
Multiple deletions or a single deletion in mtDNA can also occur as somatic mutations. Small truncated mtDNAs with large deletions (for example, 30% of the total length) can be maintained in mitochondria if the region involved in replication (mtDNA control region or the D-loop region) is intact. Replication of deleted mtDNAs can be completed in a shorter time and they may increase in abundancy preferentially (27,28).
Probably by chance, human mtDNA has two identical 13-bp sequences separated by 4,977 bp ( Figure 1 ), and the ~5-kb DNA stretch between the two sites is likely to be lost (called "common deletion"). This suggests that a repair system working on mtDNA is similar to microhomology-mediated end joining, one of the nuclear DNA repair systems (29) , and a mtDNA replication-dependent repair pathway (30), although mtDNA was previously thought to lack efficient DNA repair mechanisms.
Our sensitive quantitative PCR (qPCR) method for assaying deleted mtDNA in mutant mtDNA polymerase (Polg) knock-in mice, showed that multiple deleted mtDNAs were more abundantly accumulated in the neural tissues (28) . Although neurons are in a post-mitotic state, mtDNAs in the cells are actively metabolized (i.e., replicated and degraded). Pulse labeling of mtDNA using 5-bromo-2-deoxyuridie (BrdU) incorporation revealed that the time to reach the half maximum levels of BrdU incorporation was shortened in the brain (approximately 4 hours) compared to the liver (28) . The small truncated mtDNAs are able to be replicated and transcribed, and thus produce mutant mitochondrial proteins, which accelerate the vicious cycle of ROS in mitochondria (16) .
In the era of next-generation sequencing (NGS), new problems have emerged:
NGS helps us to examine mtDNA but it is difficult to distinguish between heteroplasmy and sequence errors. The presence of mtDNA-like sequences in the nuclear genome (nuclear
mitochondrial sequences) is also a major obstacle (31) . The human mtDNA genes are still being transferred into the nuclear DNA, and thereby a number of nuclear mitochondrial sequences exist across the nuclear genome. During the human lineage of evolution, mutations have occurred in the nuclear mitochondrial sequences, which are likely to produce spurious variant calls. To reduce the risk, a bioinformatics pipeline, MToolBox, will be helpful, which filters out nuclear mitochondrial sequences and also reconstructs the mtDNA sequence from NGS data (32) .
In addition to point mutations and deletions, depletion of mtDNA should also be considered as a predisposing factor for mitochondrial diseases and related disorders (33) . In most cases of mtDNA depletions, nuclear mutations in the enzymes for mtDNA replication are involved (33) . To detect depletion of mtDNA or to measure mtDNA copy number, qPCR can be performed using primers targeting specific regions of mtDNA (for example, the D-loop region, MT-CO1 genes; see Figure 1 ). Primers and probes should be carefully designed and validated as many of the nuclear mitochondrial sequences are almost identical to the mtDNA sequence.
The Lesson from Parkinson's Disease
There are many diseases in which mitochondrial dysfunction is involved ( What the lesson from PD tells is to focus not on mtDNA polymorphisms in peripheral tissues but on somatic mtDNA mutations in tissues responsible for the disease. For brain disorders, studying patients with mitochondrial diseases and comorbid mood disorders will ultimately be informative and lead to drug targets and understanding the mental illnesses (16) .
MtDNA Variants in Mood Disorders
Over the past 20 years a number of studies have been reported that have explored mtDNA variants in patients with psychiatric diseases (46, 47) . The mtDNA variants explored included polymorphisms, rare variants, heteroplasmic mutations causative for mitochondrial diseases such as the MELAS mutation m.3243A>G (48) , and other somatic mutations including the common deletion (49) (50) (51) (52) (53) .
Most of the reported genetic association studies of mtDNA polymorphisms and mood disorders were performed in small sample size, and cannot be considered as robust findings at the current standard. Hundreds of mtDNA polymorphisms can be tested using recent SNP arrays which are used for genome-wide association study (GWAS) analyses. A modest association of mtDNA polymorphisms m.3666G>A and m.15784T>C with bipolar disorder (BD) was detected in GWAS (965 cases and 3,938 controls) (52) . Even if in a larger-scale association study some mtDNA polymorphism associations will be found to be significant after correcting for multiple testing, they are not likely to bring us closer to connecting the polymorphisms and neuroscience because the odds ratios are expected to be low. Contrary to polymorphism (common variants), rare variants of mtDNA, which are detected using whole-genome sequencing or mtDNA resequencing array, could provide explicit cues to the involvement of aberrant mtDNA or mitochondrial dysfunction in the disease. Vawter and his colleagues sequenced entire mtDNAs (14 BD cases, 15 major depression (MD) cases, and 20 controls) and identified two very rare variants, m.114C>T
and m.16300A>G, in patients with BD (the world-wide frequencies of these variants were less than 0.004) (54) . "Private mutations" that had not been found in controls so far were not identified in the study. The same is equally true of other mtDNA variants, which were once identified as private mutations in patients with mood disorders (52, (55) (56) (57) , but almost all of M A N U S C R I P T
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10 them now turn out to be polymorphisms or rare variants with one exception: m.4564G>A
found in a patient with BD (55).
Another line of studies is the measurement of mtDNA copy number in the brain (58,59), peripheral cells (60, 61) , and plasma (62) . Quantification of mtDNA copy number in the brain is particularly important in the study of mood disorders, as the copy number has implication for biogenesis and turnover of mitochondria (63), and the activity and the structural change of mitochondrial in neurons are crucial for proper synaptic functioning (64, 65) . Although the regulation of mtDNA copy number is complex and the sampling methods affect the apparent mtDNA copy number, it should be investigated in a large number of samples in a refined way.
In order to investigate the link between mtDNA variants and psychiatric diseases, it is undoubtedly reasonable to examine somatic mtDNA mutations in the tissues responsible for the diseases, just as mtDNA mutations in neurons of the SN should be examined in PD (45) . The common deletion was quantified in candidate brain regions such as prefrontal cortex, anterior cingulate cortex, amygdala, caudate nucleus, dorsolateral prefrontal cortex, hippocampus, nucleus accumbens, and others, which have been implicated by magnetic resonance imaging and other methods (66) , and found an increase in the level of the common deletion in BD in brain (49) (50) (51) (52) (53) 67) . To focus on somatic mtDNA mutations, however, brings another question: are the somatic mutations observed an effect of medication (68) (69) (70) or the cause or the consequence of the disease -the mtDNA neuroplasticity hypothesis (16, 71) . To investigate such questions, an alternative approach based on animal models would be useful.
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There has been an alternative approach which focuses on the mental condition of mitochondrial disease patients since the publication by Fattal et al. (72) . Although sample sizes were small, they gave a substantially consistent result, namely that MD is present in about half of mitochondrial disease patients and BD is present in 7-21% (Table 1) 
Beyond the MtDNA Variants
To (96) . As a result, deleterious POLG variants were significantly enriched in patients; however, the frequency of carriers of the deleterious variants was low in patients with BD: variants predicted as deleterious, 2.4%; deleterious variants biochemically defined, 2.3%; CPEO-related mutations, 0.38%.
Genetic and clinical studies point out that idiopathic mood disorders are heterogeneous (87, (97) (98) (99) , in which causative genetic factors vary, endophenotypes vary, and psychiatric manifestations vary (but the core symptoms of mood disorders are present).
This suggests that multiple brain regions, circuits, or neurons are affected in individual patients and also in the patient population. We are starting on the road to identify each of the affected sites as the genetic risk factors have been emerging (98) (99) (100) . In such a situation, to study mitochondrial disease patients and of animal models with mtDNA mutations will provide a powerful clue to identify the affected sites in brains of patients with idiopathic mood disorders because they undergo a variety of symptoms, including the core symptoms of mood disorders, and they have damaged neurons in the brain (10, 88, 101, 102) .
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